BioSpace News Archive

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will participate in Panel #3: Taming the Severe Disease Presentations at the B. Riley FBR Virtual Infectious Disease Summit – Therapeutics Day on Tuesday, July 21, 2020 at 2:10 p.m. ET.

BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China

RESOLUTE 2.0, an industry-first SARS-CoV-2 direct multiplex Reverse-Transcription Polymerase-Chain-Reaction assay kit co-developed by Singapore’s Agency for Science Technology and Research and DSO National Laboratories, has been made available for clinical use in Singapore by Advanced MedTech Holdings, a global medical technology leader.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced that it has entered into definitive agreements for a $25 million equity financing.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, is pleased to announce its CEO Maria Maccecchini, Ph.D. will present the Company’s novel approach to treating PD at the University of Pennsylvania Perelman School of Medicine’s Parkinson’s Disease and Movement Disorders Center.

Transitional Pass-Through Payment Reimburses Hospital Outpatient and Ambulatory Surgical Centers for Incremental Cost of AUGMENT in Hindfoot and Ankle Fusion Procedures

Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance of Tanzania.

Windtree Therapeutics, Inc., a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced John Hamill has been appointed Senior Vice President, Chief Financial Officer.

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

Lexicon Pharmaceuticals, Inc., announced that four posters highlighting XERMELO® will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference.